Dataset: Expression Profiling of Mixed Lineage Leukemia Cells Treated with a Potent Small-Molecule DOT1L Inhibitor
Cell lines bearing MLL translocations (MV4-11 and MOLM-13) were treated with a potent, selective inhibitor of the DOT1L histone methyl...
Cell lines bearing MLL translocations (MV4-11 and MOLM-13) were treated with a potent, selective inhibitor of the DOT1L histone methyl transferase. Treatment of MLL-rearranged cell lines with the DOT1L inhibitor selectively inhibits H3K79 methylation and blocks expression of leukemogenic genes. Here we provide expression profiling data of cells treated with DOT1L inhibitor or vehicle control. MV4-11 cells were treated with 3 uM EPZ004777 (DOT1L inhibitor) or vehicle control (0.1% DMSO) for 2, 4 and 6 days. MOLM-13 cells were treated with 3 uM EPZ004777 (DOT1L inhibitor) or vehicle control (0.1% DMSO) for 6 days. For each unique conditon, 3 biological replicates were generated for expression profiling.
- Species:
- human
- Samples:
- 24
- Source:
- E-GEOD-29828
- Updated:
- Dec.12, 2014
- Registered:
- Sep.16, 2014
Sample | GROWTH CONDITIONS | CELL LINE | AGENT | BIOLOGICAL REP | TIME | CELL LINE DESCRIPTION |
---|---|---|---|---|---|---|
GSM739148 | IMDM with 10% FBS | MV4-11 | EPZ004777 | 1 | day 2 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739149 | IMDM with 10% FBS | MV4-11 | EPZ004777 | 2 | day 2 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739150 | IMDM with 10% FBS | MV4-11 | EPZ004777 | 3 | day 2 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM73915 | IMDM with 10% FBS | MV4-11 | vehicle | 1 | day 2 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739152 | IMDM with 10% FBS | MV4-11 | vehicle | 2 | day 2 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739153 | IMDM with 10% FBS | MV4-11 | vehicle | 3 | day 2 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739154 | IMDM with 10% FBS | MV4-11 | EPZ004777 | 1 | day 4 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739155 | IMDM with 10% FBS | MV4-11 | EPZ004777 | 2 | day 4 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739156 | IMDM with 10% FBS | MV4-11 | EPZ004777 | 3 | day 4 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739157 | IMDM with 10% FBS | MV4-11 | vehicle | 1 | day 4 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739158 | IMDM with 10% FBS | MV4-11 | vehicle | 2 | day 4 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739159 | IMDM with 10% FBS | MV4-11 | vehicle | 3 | day 4 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739160 | IMDM with 10% FBS | MV4-11 | EPZ004777 | 1 | day 6 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM73916 | IMDM with 10% FBS | MV4-11 | EPZ004777 | 2 | day 6 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739162 | IMDM with 10% FBS | MV4-11 | EPZ004777 | 3 | day 6 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739163 | IMDM with 10% FBS | MV4-11 | vehicle | 1 | day 6 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739164 | IMDM with 10% FBS | MV4-11 | vehicle | 2 | day 6 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739165 | IMDM with 10% FBS | MV4-11 | vehicle | 3 | day 6 | biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment) |
GSM739166 | RPMI with 10% FBS | MOLM-13 | EPZ004777 | 1 | day 6 | acute myeloid leukemia (MLL-AF9 rearrangement) |
GSM739167 | RPMI with 10% FBS | MOLM-13 | EPZ004777 | 2 | day 6 | acute myeloid leukemia (MLL-AF9 rearrangement) |
GSM739168 | RPMI with 10% FBS | MOLM-13 | EPZ004777 | 3 | day 6 | acute myeloid leukemia (MLL-AF9 rearrangement) |
GSM739169 | RPMI with 10% FBS | MOLM-13 | vehicle | 1 | day 6 | acute myeloid leukemia (MLL-AF9 rearrangement) |
GSM739170 | RPMI with 10% FBS | MOLM-13 | vehicle | 2 | day 6 | acute myeloid leukemia (MLL-AF9 rearrangement) |
GSM73917 | RPMI with 10% FBS | MOLM-13 | vehicle | 3 | day 6 | acute myeloid leukemia (MLL-AF9 rearrangement) |